Market News & Trends
EyePoint Pharmaceuticals Announces Expanded License Agreement With Betta Pharmaceuticals
EyePoint Pharmaceuticals, Inc. recently announced the execution of a license agreement with Betta Pharmaceuticals Co. Ltd. to develop and commercialize EYP-1901 in Mainland China, Hong…
BioXcel Therapeutics Announces First Patient Dosed in TRANQUILITY II Phase 3 Trial for Acute Treatment of Agitation in Patients With Alzheimer’s Disease
BioXcel Therapeutics, Inc. recently announced the first patient has been dosed in the Phase 3 TRANQUILITY II study of BXCL501, the company’s proprietary, orally dissolving…
DepYmed Receives FDA Rare Pediatric Disease & Orphan Drug Designations for its Lead Clinical Candidate for the Treatment of Rett Syndrome
DepYmed Inc. recently announced that the US FDA has granted Rare Pediatric Disease and Orphan Drug designations for its lead clinical candidate, a small molecule…
Hepion Pharmaceuticals Announces Clinical Collaboration With HepQuant in Phase 2b NASH Trial
Hepion Pharmaceuticals, Inc. recently announced it has entered into a clinical collaboration with HepQuant, a Denver-based, privately held company with novel, proprietary investigational technology for…
Lubrizol Life Science Health Launches Innovative Apisolex(TM) Technology to Improve Solubility & Simplify Manufacturing of Parenteral Drug Products
Lubrizol Life Science (LLS) Health, a global leader in accelerating success and innovation in pharmaceutical development, has launched Apisolex, a novel solubility-enhancing excipient for use in….
Nevakar Injectables Sells Six Development-Stage, Ready-to-Use Injectable Product Candidates to Endo Ventures Limited
Nevakar Injectables Inc. recently announced it has entered into an asset sale agreement with Endo Ventures Limited, a subsidiary of Endo International plc (Endo) for the sale of six of its….
Rancho Biosciences Launches the Single Cell Data Science Consortium With Four Charter Members
Rancho Biosciences recently announced the launch of its Single Cell Data Science (SCDS) pre-competitive consortium. The 3-year effort is supported in collaboration with the following…
Vaxxinity Receives FDA Fast Track Designation for UB-311 for Treatment of Alzheimer’s Disease
Vaxxinity, Inc. recently announced that UB-311, an anti-amyloid beta immunotherapeutic vaccine, has been granted Fast Track designation by the US FDA for the treatment of Alzheimer’s disease…..
Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome
Rhythm Pharmaceuticals, Inc. recently announced the presentation of new data supporting the potential for setmelanotide to treat the early onset obesity, hyperphagia, and metabolic impairment…
FDA Has Granted Veru a Pre-Emergency Use Authorization Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study
Veru Inc. recently announced the FDA has granted the company a pre-Emergency Use Authorization (EUA) meeting on May 10, 2022, for the positive Phase 3…
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi
Denali Therapeutics Inc. recently announced its partner Sanofi has commenced dosing in a Phase 2 study, named HIMALAYA, of SAR443820 (DNL788) in individuals with amyotrophic…
Harpoon Therapeutics & Roche to Collaborate on Clinical Trials to Study Novel Immuno-Oncology Combination for Small Cell Lung Cancer
Harpoon Therapeutics, Inc. recently announced it has entered into a clinical supply agreement with F. Hoffmann-La Roche Ltd (Roche) to supply atezolizumab (Tecentriq) for use in the….
Catalent Expands Nasal Drug Development & Manufacturing Capabilities at North Carolina Facility
Catalent recently announced it has successfully completed a significant expansion of its nasal capabilities at its Morrisville, Research Triangle Park (RTP), North Carolina, facility, to…
Copley Launches New Semi-Automation Tool for Inhaled Product Testing
Copley Scientific, the global leader in inhaled product testing equipment, has launched the new Gentle Rocker 100i, a simple, cost-effective device that boosts the productivity and repeatability of….
QSAM Biosciences Doses First Patient in its Clinical Trial for Radiopharmaceutical Drug Candidate for the Treatment of Bone Cancer
QSAM Biosciences Inc. recently announced the first patient commenced treatment in its clinical trial evaluating CycloSam in patients with metastatic bone cancer. QSAM previously announced…
Skye Bioscience Engages Clinical Trial Site for Phase 1 Study in Agreement With CMAX Clinical Research
Skye Bioscience, Inc. recently retained CMAX Clinical Research to facilitate enrollment of and drug administration to healthy volunteers for Skye’s Phase 1 study of its…
HiberCell Announces First Patients Dosed in Phase 2 Clinical Trial of Odetiglucan in Combination with KEYTRUDA in Adult Patients With Metastatic, Hormone-Refractory Breast Cancer
HiberCell recently announced the first patients have been dosed in a Phase 2 clinical trial of odetiglucan plus KEYTRUDA (pembrolizumab) for the treatment of metastatic,…
Vaxxinity Completes Enrollment in Part B of UB-312 Phase 1 Clinical Trial for Parkinson’s Disease
Vaxxinity, Inc. recently announced it has completed patient enrollment for Part B of its ongoing Phase 1 clinical trial of UB-312 in Parkinson’s disease (PD). Vaxxinity’s…
Caladrius Biosciences & Cend Therapeutics Announce Definitive Merger Agreement
Caladrius Biosciences, Inc. and Cend Therapeutics, Inc. recently announced the companies have entered into a definitive merger agreement under which Cend will merge with a wholly owned subsidiary of….
Symeres Acquires Organix, Adding Lipids Expertise & Strategic Foothold in the US
Symeres recently announced the acquisition of Organix Inc., a US-based specialized organic chemistry services provider with a focus on lipids…..